Glycolytic Reprogramming in Silica-Induced Lung Macrophages and Silicosis Reversed by Ac-SDKP Treatment

Int J Mol Sci. 2021 Sep 17;22(18):10063. doi: 10.3390/ijms221810063.

Abstract

Glycolytic reprogramming is an important metabolic feature in the development of pulmonary fibrosis. However, the specific mechanism of glycolysis in silicosis is still not clear. In this study, silicotic models and silica-induced macrophage were used to elucidate the mechanism of glycolysis induced by silica. Expression levels of the key enzymes in glycolysis and macrophage activation indicators were analyzed by Western blot, qRT-PCR, IHC, and IF analyses, and by using a lactate assay kit. We found that silica promotes the expression of the key glycolysis enzymes HK2, PKM2, LDHA, and macrophage activation factors iNOS, TNF-α, Arg-1, IL-10, and MCP1 in silicotic rats and silica-induced NR8383 macrophages. The enhancement of glycolysis and macrophage activation induced by silica was reduced by Ac-SDKP or siRNA-Ldha treatment. This study suggests that Ac-SDKP treatment can inhibit glycolytic reprogramming in silica-induced lung macrophages and silicosis.

Keywords: N-acetyl-seryl-aspartyl-lysyl-proline; glycolysis; inflammation; macrophages; silicosis.

MeSH terms

  • Animals
  • Fibroblasts / metabolism
  • Glycolysis*
  • Inflammation / drug therapy
  • Lung / drug effects*
  • Macrophages / drug effects*
  • Macrophages, Alveolar / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Oligopeptides / pharmacology
  • Pulmonary Fibrosis / metabolism
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Wistar
  • Silicon Dioxide / adverse effects*
  • Silicosis / therapy*

Substances

  • Oligopeptides
  • RNA, Small Interfering
  • Silicon Dioxide
  • goralatide